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Ad Anna, Margherita e Giacomo. 
 
I’m not afraid 
they’ll stamp me flat. 
Grass stamped flat 
soon becomes a path. 
 
Nessuna paura 
che mi calpestino. 
Calpestata, l'erba 
diventa un sentiero. 
 
Blaga Dimitrova 
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Summary 
More than 80% of all mammary gland masses in cats are malignant and the behavior of these tumors 
is characterized by local invasion into the vasculature and surrounding tissues and by metastasis to 
distant locations, including the draining lymph nodes, lungs, pleura and liver. Due to this aggressive 
biological behavior, feline mammary adenocarcinoma (FMA) requires aggressive treatment: 
surgical excision, chemotherapy, immunotherapy and radiation therapy or combinations of these 
treatments. Surgical approach has been shown to affect progression-free interval (PFSI) when 
radical mastectomy is compared to regional mastectomy. Based on these data performing radical 
mastectomy of the affected mammary chain is a well-established recommendation regardless of 
tumor size. A more challenging question that has received little attention in the veterinary literature 
is whether to perform unilateral (URM) versus bilateral radical mastectomy (BRM) because of 
possible contact between individual glands, connections between the left and right mammary chains 
or the de novo development of mammary adenocarcinoma in the contralateral chain. The objectives 
of this multi-institutional retrospective study were to compare outcome among cats with mammary 
adenocarcinoma following excision with or without various systemic adjuvant therapies, and to 
evaluate the effect of surgical approach on PFSI (Progression Free Survival) ,and Disease-Specific 
Survival (DSS). 
In the Preliminary Study chapter, We conducted a preliminary analysis on clinical records (116 cats) 
from 9 Veterinary Institutions in Europe and North America that underwent surgical excision of 
FMA by URM or BRM (staged or single-session) between 1991 and 2014. Adjuvant chemotherapy 
was administered to some cats; type and dose of chemotherapy drugs were recorded. PFSI as well 
the nature of the recurrence and OS (Overall Survival Time) were also recorded. 
In this study, Median OS was not significantly longer for cats treated with BRM compared with 
URM, so no significant effect of surgical approach on OS was found. 
In the Main project chapter, We reviewed all the data, the statistical analysis, and the inclusion 
criteria: We excluded cats that underwent local or regional mastectomy, that underwent URM but 
had bilateral disease, or that had distant metastasis at the time of surgery. However, cats with 
locoregional disease alone and no distant metastases were included. Outcome data obtained from 
   
 
5 
 
107 remaining cats included post-operative complications, progression-free survival (PFSI), and 
disease-specific survival (DSS). 
Post-operative complications were significantly more likely to occur in cats undergoing BRM 
compared with URM. 
The overall median PFSI was significantly longer for cats treated with BRM compared to URM. 
The overall median DSS was significantly longer for cats treated with BRM compared with URM.  
In conclusion, the findings of this Main project support the use of the BRM for treatment of FMA 
in order to improve the PFSI and DSS. Performing BRM in a staged fashion may help to reduce 
complications. 
Riassunto 
L'incidenza dell'adenocarcinoma mammario è superiore all’80 % nel gatto. La sua natura è 
aggressiva ed è caratterizzata da invasione della struttura vascolare e dei tessuti circostanti; inoltre 
l’adenocarcinoma mammario felino tende a metastatizzare nei linfonodi tributari, polmoni, pleura e 
fegato. 
A causa della sua natura aggressiva, sono stati suggeriti trattamenti medici e chirurgici aggressivi: 
completa escissione chirurgica, chemioterapia, immunoterapia, radioterapia o una combinazione di 
questi trattamenti. 
Alcune ricerche hanno dimostrato, inoltre, come la chemioterapia adiuvante possa essere un fattore 
prognostico positivo; tuttavia in uno studio che comprendeva un gruppo di controllo, la 
chemioterapia adiuvante non ha dato alcun beneficio. 
Altri studi hanno evidenziato che la mastectomia bilaterale aumenta i tempi di ricorrenza se 
comparata con la mastectomia regionale; per questo, la mastectomia bilaterale è l'approccio 
chirurgico suggerito in caso di adenocarcinoma mammario felino a prescindere dalla dimensione 
del tumore primario. 
Tuttavia, in Medicina Veterinaria, non si è condotta ancora sufficiente ricerca se sia più indicato 
procedere con Mastectomia Monolaterale o Bilaterale a causa di un possibile contatto tra le singole 
ghiandole mammarie, a causa di una connessione tra le due file mammarie o a causa di un "de novo" 
adenocarcinoma mammario nella fila controlaterale. 
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L’obiettivo di questo studio retrospettivo multicentrico è di comparare gli “outcome” in gatti affetti 
da adenocarcinoma mammario sottoposti ad intervento di Mastectomia Monolaterale o Bilaterale. 
Le cartelle cliniche dei gatti, alcuni dei quali sono stati sottoposti a chemioterapia adiuvante, sono 
state analizzate per valutare gli effetti dei differenti approcci chirurgici sui tempi di ricorrenza e di 
sopravvivenza specifica. 
Nella prima parte della Tesi (Preliminary Study), è stato condotto uno studio preliminare 
retrospettivo sui dati provenienti dalle cartelle cliniche di 116 gatti affetti da adenocarcinoma 
mammario, sottoposti a Mastectomia Monolaterale o Bilaterale tra il 1991 e il 2014 presso 9 Centri 
di Referenza in Europa ed in Nord America. 
Alcuni gatti sono stati sottoposti a chemioterapia adiuvante; il protocollo chemioterapico (tipo e 
dosaggi) insieme ai tempi di ricorrenza e sopravvivenza globale sono stati statisticamente analizzati. 
Il tempo di sopravvivenza globale non è risultato essere statisticamente maggiore tra i gatti sottoposti 
a Mastectomia Bilaterale rispetto a quelli sottoposti a Mastectomia Monolaterale. 
Nella seconda parte della Tesi (Main Project), abbiamo rianalizzato tutte le cartelle cliniche, 
utilizzando un differente modello statistico e modificando i criteri di inclusione: abbiamo escluso i 
gatti sottoposti a mastectomia locale o regionale, quelli sottoposti a mastectomia monolaterale 
nonostante fossero coinvolte entrambe le file mammarie e quelli che presentavano metastasi in altri 
distretti. Tuttavia, i gatti con tumore locoregionale ma in assenza di metastasi sono stati inclusi nello 
studio. Dopo revisione, 107 rimanenti gatti sono stati inclusi nello studio; in questo studio abbiamo 
posto particolare attenzione alle complicazioni post operatorie, ai tempi di ricorrenza e di 
sopravvivenza specifica. 
Le complicazioni post chirurgiche sono risultate essere statisticamente più significative nei gatti 
sottoposti a Mastectomia Bilaterale rispetto a quella Monolaterale. 
I tempi medi di ricorrenza medi sono risultati essere statisticamente maggiori nei gatti sottoposti a 
Mastectomia Bilaterale rispetto a quelle Monolaterale; i tempi medi di sopravvivenza specifica sono 
risultati essere statisticamente maggiori nei gatti sottoposti Mastectomia Bilaterale rispetto a quella 
Monolaterale. 
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In conclusione, i risultati supportano il ricorso alla Mastectomia Bilaterale per il trattamento 
chirurgico dell'adenocarcinoma mammario felino, in quanto sembra prolungare il tempo medio di 
ricorrenza e sopravvivenza specifica. La Mastectomia Bilaterale, infine, eseguita in due fasi sembra 
ridurre le complicazioni post chirurgiche. 
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List of Abbreviations 
 
BRM Bilateral mastectomy 
OS Overall Survival 
DSS Disease-specific survival 
FMA Feline mammary adenocarcinoma 
PFSI Progression-free survival 
URM Unilateral Mastectomy 
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Abstract 
Introduction – The objectives of this study were to evaluate the effect of surgical approach on 
complication rate, progression-free interval (PFSI) and overall survival (OS) in feline mammary 
adenocarcinoma (FMA). 
Methods – Cats (n=116) that underwent surgical excision of FMA by unilateral (URM) or bilateral 
(staged or single-session) radical mastectomy (BRM) were included. Log rank tests were used to 
compare progression and survival distributions according to mastectomy type. Cox proportional 
hazard regression was used to model variables associated with PFSI and OS. 
Result - Complications were significantly (p = 0.037) more likely after single-session BRM (14/33, 
42.4%) compared to URM or staged BRM (20/83, 24.1%). Median PFSI was 380 days for all cats, 
and was longer (p=0.005) for cats treated with BRM (861 days) compared with URM (298 days). 
In the multivariable model, risk factors for disease progression included URM (HR 2.74, 95%CI 
1.55 to 4.86), tumor ulceration (HR 3.19, 95%CI 1.50 to 6.81), and lymphatic or vascular invasion 
(HR 1.72, 95%CI 1.05 to 2.83). Risk factors for death included development of regional or distant 
metastasis (HR 2.34, 95%CI 1.36 to 4.00) and lymphatic or vascular invasion (HR 1.86, 95%CI 1.11 
to 3.10). Treatment with chemotherapy was associated with reduced hazard of death (HR 0.49, 
95%CI 0.29 to 0.81). 
Conclusion – These findings support the use of BRM for treatment of FMA to improve the PFSI 
although no significant effect of surgical approach on OS was found. To reduce complications 
associated with BRM, performing the procedure in a staged fashion is recommended. 
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Introduction  
More than 80% of all mammary gland masses in cats are malignant and the behavior of these tumors 
is characterized by local invasion into the vasculature and surrounding tissues and by metastasis to 
distant locations, including the draining lymph nodes, lungs, pleura and liver. Due to this aggressive 
biological behavior, feline mammary adenocarcinoma (FMA) requires aggressive treatment: 
surgical excision, chemotherapy, immunotherapy and radiation therapy or combinations of these 
treatments.   
Adjuvant chemotherapy has been suggested to have a beneficial prognostic effect in some studies 
(4) but in one study that included a control population that did not receive adjuvant chemotherapy 
no obvious benefit from chemotherapy was seen.(6)   
Surgical approach has been shown to affect progression-free interval (PFSI) when radical 
mastectomy is compared to regional mastectomy.(1) Based on these data performing radical 
mastectomy of the affected mammary chain is a well-established recommendation regardless of 
tumor size. A more challenging question that has received little attention in the veterinary literature 
is whether to perform unilateral (URM) versus bilateral radical mastectomy (BRM) because of 
possible contact between individual glands, connections between the left and right mammary chains 
or the de novo development of mammary adenocarcinoma in the contralateral chain.   
The objectives of this multi-institutional retrospective study were to compare outcome among cats 
with mammary adenocarcinoma following excision with or without various systemic adjuvant 
therapies, and to evaluate the effect of surgical approach on PFSI and overall survival (OS). Our 
primary null hypothesis was that no differences would exist between URM and BRM in terms of 
PFSI and OS. Secondary hypotheses were that no differences would exist in the surgical 
complication rate of URM versus BRM whether performed in a single-session or staged approach. 
Additionally we hypothesized that adjuvant chemotherapy would prolong PFSI and OS compared 
with those receiving no systemic adjuvant therapy.   
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Methods 
Animals - Cats diagnosed with FMA at 9 veterinary institutions in North America and Europe 
between 1991 and 2014 were included in this study. Medical records were reviewed from the 
participating centers and telephones interviews were conducted with owners or referring 
veterinarians to assess long-term outcome. 
Criteria for selection of cases - Inclusion criteria for entry into the study were as follows: Cats that 
had a complete medical record and underwent surgical excision of histopathologically proven 
mammary adenocarcinoma with URM or BRM(single session or staged). Cats were excluded if they 
underwent simple or regional mastectomy. 
Case data -Information collected from the medical record included age at time of surgery, weight, 
sex, breed, use of progestin, previous pregnancy, whether an ovariectomy or ovariohysterectomy 
had been performed, time from onset of clinical signs to presentation to a veterinarian. Information 
recorded from diagnostic imaging studies included abnormalities present on thoracic radiography 
and abdominal ultrasound prior to first surgery. The number of mammary masses, location of 
mammary masses (right, left or present on both sides) and which specific gland(s) was affected 
(axillary, thoracic, abdominal and inguinal) were recorded along with the diameter of largest 
mammary mass (measured in cm) and presence or absence of ulceration. From these results a TNM 
stage was designated for each cat based on the clinical and diagnostic imaging findings using the 
modified World Health Organization (WHO) staging system.1 
Surgical variables that were recorded included the surgical procedure performed; URM or BRM 
(single session or staged). Surgery time for the mastectomy was recorded and in the case of staged 
BRM the surgery time for each of the two staged procedures was recorded as a separate event. If a 
lymphadenectomy was performed the lymph nodes removed were noted. Intra- and post-operative 
complications were recorded and compared between procedures. 
The results of histological evaluation of all resected mammary gland tissue as well as lymph nodes 
was recorded. Tumor grade based on degree of differentiation and evidence of lymphatic and 
vascular invasion was also recorded when available.            
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Adjuvant chemotherapy was administered to some but not all cats.The number of doses and type of 
chemotherapy drugs administered was recorded in each case. Whether or not the patient completed 
the prescribed course of chemotherapy was also recorded. 
Outcomes -Progression free interval was defined as the time from mastectomy until documentation 
of local tumor recurrence or regional or distant metastasis. Progression free interval as well as the 
nature of the recurrence (local versus distant) were also recorded. Overall survival time was defined 
as the time from original mastectomy to death.  
Statistical analysis - Baseline characteristics were examined and summary statistics described for 
all measured variables. Categorical variables were reported as numbers and percentages. Normal 
distribution of continuous variables was evaluated using histograms and the Shapiro-Wilk test, and 
results were reported as mean (standard deviation) or median (range). Comparisons of baseline 
characteristics were made between mastectomy groups using 2 or Fisher exact tests for categorical 
variables, and independent t tests or Mann-Whitney U tests for continuous variables. For cats 
undergoing staged BRM, first and second surgical times were compared using the signed rank test 
for pairwise comparisons. All tests were two-sided and results were considered statistically 
significant if p  .05. 
Cats lost to follow-up or alive at the time of data collection were censored at their last recorded live 
dates. Kaplan-Meier product limit method was used to describe unadjusted PFSI and OS for all cats. 
Log rank tests were used to compare progression and survival distributions according to mastectomy 
type (URM vs. BRM). Cox proportional hazard regression was used to model variables associated 
with PFSI and OS. Univariate analyses were performed and covariates with Wald p < 0.25 were 
tested for inclusion in the multivariate models. A forward selection method was used for multivariate 
modeling, with covariates retained if their likelihood ratio test and/or Wald test p values were  .05, 
or if covariates were confounding the association of interest (defined as >15% change in hazard 
ratio).  In instances where the likelihood ratio test could not be used due to missing covariate data, 
AIC was used for model comparison. Proportional hazards assumptions were evaluated with 
Shoenfeld residuals using the score test, with p > .05 considered acceptable. Overall model fit was 
assessed using deviance and Cox-Snell residuals.  
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Results 
General characteristics - Reports of 116 eligible cats from 9 different veterinary hospitals were 
identified, among which 69 (59.5%) had URM, and 47 (40.5%) had BRM. In the BRM group, 33 
(70.2%) surgeries were performed as a single-stage procedure, and 14 (29.8%) were staged in two 
separate unilateral procedures. Demographic and staging characteristics of the cats are reported in 
Table 1, according to type of mastectomy performed. 
Table 1:  Characteristics of 116 cats undergoing radical mastectomy for treatment of mammary 
gland carcinoma, according to mastectomy type (unilateral vs bilateral). Data are presented as 
number (%) except where indicted. 
  Unilateral 
(n=69) 
Bilateral 
(n=47) 
P value 
Institution 
University of Pennsylvania 
University of California Davis 
Colorado State University 
 Ontario Veterinary College 
Alta Vista Animal Hospital 
Clinica Veterinaria Nerviano 
University of Turin 
University of Florida 
University of Tennessee 
  
21 (30.4) 
16 (23.2) 
12 (17.4) 
4 (5.8) 
0 (0.0) 
7 (10.1) 
4 (5.8) 
3 (4.3) 
2 (2.9) 
  
11 (23.4) 
4 (8.5) 
7 (14.9) 
6 (12.8) 
9 (19.1) 
1 (2.1) 
3 (6.4) 
3 (6.4) 
3 (6.4) 
<0.001 
Age, y, median (range) 11 (1-16) 11 (3-18) 0.43 
Weight, kg, median (range) 4.4 (2.3-7.0) 4 (2.7-7.8) 0.11 
Sex      0.90 
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Male castrated 
          Female intact 
          Female spayed 
1 (1.4) 
9 (13.0) 
59 (85.5) 
1 (2.1) 
7 (14.9) 
44 (83.0) 
Breed  
          Domestic short hair 
          Domestic long hair 
Siamese 
Other pure breed 
  
39 (56.5) 
19 (27.5) 
5 (7.2) 
6 (8.7) 
  
25 (53.2) 
8 (17.0) 
3 (6.4) 
11 (23.4) 
0.35 
Duration of clinical signs, d, median 
(range)1 
30 (0-700) 20 (0-730) 0.64 
Number of tumors 
1 
 2-5 
>5         
  
41 (59.4) 
22 (31.9) 
6 (8.7) 
  
19 (40.4) 
18 (38.3) 
10 (21.3) 
0.07 
Location of tumors2 
Right chain 
Left chain 
Bothchains 
  
30 (47.6) 
22 (34.9) 
11 (17.5) 
  
16 (35.6) 
14 (31.1) 
15 (33.3) 
0.16 
Largest tumor diameter, cm, 
median (range)3 
2 (0.2-10.0) 2 (0.3-10.0) 0.31 
Ulcerated tumor 8 (11.6) 6 (12.8) 0.51 
TMN Stage4 
 Stage 1 (T1 N0, M0) 
  
20 (29.9) 
  
15 (33.3) 
 
0.24 
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Stage 2 (T2, N0, M0) 
Stage 3 (T1-2, N1, M0); (T3, any N, 
M0) 
  Stage 4 (any T, any N,    M1) 
16 (23.9) 
27 (40.3) 
 
4 (6.0) 
7 (15.6) 
23 (51.1) 
 
0 (0.0) 
Lymphnode metastasis4 24 (38.7) 20 (46.5) 0.55 
Histopathologic lymphatic or 
vascular invasion 
31 (44.9) 20 (42.6) 0.85 
Histopathologic surgical margins5 
 R0 (clean) 
 R1 (narrow, <2mm) 
 R2 (dirty) 
  
 
46 (74.2) 
9 (14.5) 
7 (11.3) 
  
 
37 (90.2) 
3 (7.3) 
1 (2.4) 
0.13 
  
1: data missing for 21 cats; 2: data missing for 8 cats; 3: data missing for 9 cats; 4: data missing for 
4 cats; 5: data missing for 11 cats 
The majority of cats were spayed females, but spay procedure details were often unknown. Among 
48 cats for which the type of spay procedure was known, 29(60.4%) had an ovariectomy, and 19 
(39.6%) had an ovariohysterctomy. Among 48 cats for whom parturition status was known, 12 
(25.0%) had at least one prior pregnancy, and 36 (75.0%) had never been pregnant. One cat had 
previously been treated with oral progestins. Tumor location was reported for 115 cats. The axillary 
glands were affected in 34 (29.6%) cats, thoracic glands were affected in 33 (28.7%), abdominal 
glands were affected in 43 (37.4%) cats, and inguinal glands were affected in 60 (52.2%) cats.  
Results of pre-operative staging tests were available for most cats. Chest radiographs were 
performed in 102/116 (87.9%) cats, and abdominal ultrasound was performed in 48/116 (41.4%) 
cats. Regional lymph nodes were reportedly aspirated in 21/116 (18.1%) cats.  
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Surgery and histopathology - Median surgical procedure time was 70 minutes (range 40 – 160) for 
URM (including first stage of cats treated with staged BRM), and 75 minutes (range 35 – 180) for 
single-stage BRM, and this difference was not statistically significant (p=0.84). Among cats treated 
with staged BRM, median second surgery time was 70 minutes (range 41 -115) and was not 
significantly different from first surgery time (p=0.67).  
Post-operative complications occurred in 35/116 (30.5%) cats. (Table 2) Among cats with staged 
BRM, complications occurred after the first surgery in 2 cats and after the second surgery in 3 cats. 
Complications were significantly (p = 0.037) more likely to occur among cats undergoing single-
stage BRM (14/33, 42.4%) compared to URM or staged BRM (20/83, 24.1%). One cat undergoing 
URM experienced multiple complications (incisional infection and pleural effusion). Three cats died 
in the immediate post-operative period: one cat due to cardiac arrest after URM, and two cats due 
to respiratory failure attributed to excessive wound closure tension after single-stage BRM.  
Table 2: Post-operative complications in 116 cats undergoing unilateral or bilateral radical 
mastectomy for mammary gland carcinoma.  All values are reported as No. (%) 
  
  Unilateral  
N=69  
Bilateral 
Staged   
N=14  
Bilateral 
Single   
N= 33  
Total  
N= 116  
Infection/dehiscence  12 (17.4)  2 (14.3)  8 (24.2)  22 (19.0)  
Seroma  1 (1.5)  1 (7.1)  3 (9.1)  5 (4.3)  
Abdominal hernia  1 (1.5)  0 (0.0)  1 (3.0)  2 (1.7)  
Respiratory distress  1 (1.5)  0 (0.0)  2 (6.1)  3 (2.6)  
Other  2 (2.9)1  2 (14.3)2  0 (0.0)  4 (3.4)  
1: cardiac arrest (1), fever (1) 2: seizures (1), esophageal stricture (1)  
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Histopathologic evaluation and terminology used to describe tumors was not uniform across all 
surgical samples. The majority of tumors were described simply as adenocarcinoma, but other 
mammary carcinoma diagnoses were also reported, including simple, cystic, tubular, 
tubulopapillary, tubuloacinar, papillary, ductal, intraductal, infiltrative, secretory, complex, lobular, 
basaloid, scirrous, and comedo carcinomas. Heterogeneity of descriptions precluded further 
classification and analysis on the basis of histopathologic type. Degree of tumor differentiation was 
reported for 60 cats; 13/60 (21.7%) well differentiated, 22/60 (36.7%) moderately differentiated, 
and 25/60 (41.7%) poorly differentiated.  Lymphatic invasion was reported in 43/116 (37.1%) cats 
and vascular invasion was reported in 16/116 (13.8%) cats. Tissue margins were evaluated in 103 
cats and were clean (>2mm) in 83/103 (80.6%) cats, narrow (0-2mm) in 12/103 (11.7%) cats, and 
incomplete in 8/103 (7.8%) cats. Among 105 cats for which regional lymph nodes were evaluated 
histologically, 44 (41.9%) had evidence of lymph node metastasis.  
  
Adjuvant therapy - In addition to the three cats that died in the post-operative period, two cats were 
lost to follow-up 1 and 4 days after surgery. Therefore, follow-up information was analyzed for 111 
cats.   
Adjuvant chemotherapy was administered to 55/111 (49.5%) cats, including 30/66 (45.5%) that 
underwent URM and 25/45 (55.6%) that underwent BRM. There was no significant difference 
(p=0.55) in the proportion of cats receiving chemotherapy between mastectomy groups. 
Doxorubicin was administered to 46 cats for a median of 4 doses (range 1-6); 9 of these cats were 
also treated concurrently with cyclophosphamide for a median of 4 doses (range 2-5). Carboplatin 
was also administered to 15 cats, including 12 that also received doxorubicin. The remaining 6 cats 
received other chemotherapy drugs, including experimental liposomes (2), epirubicin (2), 
mitoxantrone (1), and Palladia and chlorambucil (1).  Following doxorubicin and/or carboplatin 
chemotherapy, 6 cats were treated with additional chemotherapy: Palladia (2), vincristine (1), 
vinorelbine (1), dacarbazine (1), vincristine, Palladia, and chlorambucil (1). Among chemotherapy-
treated cats, 42/55 (76.4%) completed the planned treatment protocol; treatment was stopped early 
in 13 cats due to progressive disease (6), non-cancer-related death (3), delayed post-operative 
complications (1), kidney disease (1), persistent neutropenia (1), and owner relocation (1). NSAIDs 
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(meloxicam or ketoprofen) were administered to 19/111 (17.1%) cats, including 9 that were also 
treated with chemotherapy. 
  
Progression free interval - Progressive disease was reported for 68/111 (61.3%) cats. Local 
recurrence and metastasis were more frequently reported following URM compared with BRM. 
(Table 3) In 5 cats treated with BRM and 19 cats treated with URM, both local recurrence and 
metastasis occurred. Among these 24 cats, the first reported event was local recurrence in 12 cats 
and metastasis in 6 cats; in the remaining 6 cats both recurrence and metastasis were identified on 
the same date. 
Table 3: Reported disease progression in 111 cats undergoing unilateral or bilateral radical 
mastectomy for mammary gland carcinoma.  All values are reported as No. (%) 
  
  Unilateral  
N=66  
Bilateral  
N=45  
P value  
No progression  21 (31.8)  27 (60.0)  0.003  
Local recurrence  31 (47.0)  9 (20.0)  0.004  
Regional or distant 
metastasis  
36 (54.5)  16 (35.6)  0.049  
Median PFSI was 380 days for all cats, and was longer (p=0.005) for cats treated with BRM (861 
days) compared with URM (298 days). (Fig 1) Median PFSI was 380 days for all cats, and was 
significantly longer (p=0.005) for cats treated with BRM (861 days) compared with URM (298 
days). 
On univariable Cox regression, institution, age, body weight, duration of clinical signs prior to 
radical mastectomy, largest tumor diameter, number of masses, post-operative incision infection, 
and treatment with chemotherapy were not associated with PFI; tumor location, tumor ulceration, 
type of mastectomy, lymph node metastasis at the time of surgery, and lymphatic or vascular 
   
 
20 
 
invasion were associated (p>0.25) with PFI and were tested in the multivariable model. In the final 
multivariable model, risk factors for disease progression included URM (HR 2.74, 95%CI 1.55 to 
4.86), tumor ulceration (HR 3.19, 95%CI 1.50 to 6.81), and lymphatic or vascular invasion noted 
on histopathology (HR 1.72, 95%CI 1.05 to 2.83).  
  
Figure 1: Kaplan Meier survival distribution for progression free survival time in 111 cats with 
mammary carcinoma, according to type of mastectomy. Vertical ticks indicate censored 
observations.  
Overall survival –Median OS was 496 days for all cats, and was not significantly longer (p=0.191) 
for cats treated with BRM (623 days) compared with URM (455 days). (Figure 2) At the time of 
analysis, 25 cats were lost to follow up a median of 560 days after surgery (range 17 to 3278), 17 
cats were alive, and 69 cats had died, with 58 deaths attributed to mammary disease and 11 attributed 
to unknown or unrelated causes. On univariable Cox regression, institution, body weight, duration 
of clinical signs, largest tumor diameter, number of masses, type of mastectomy, post-operative 
incision infection, and development of local recurrence were not associated with OS; age, tumor 
location, tumor ulceration, lymph node metastasis at the time of surgery, treatment with 
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chemotherapy, and development of distant metastasis were associated (p>0.25) with OS and were 
tested in the multivariable model. In the final multivariable model, after adjusting for age, risk 
factors for death included development of regional or distant metastasis (HR 2.34, 95%CI 1.36 to 
4.00), and lymphatic or vascular invasion noted on histopathology (HR 1.86, 95%CI 1.11 to 3.10); 
treatment with chemotherapy was associated with reduced hazard of death (HR 0.49, 95%CI 0.29 
to 0.81). 
In the multivariable model, risk factors for disease progression included URM (HR 2.74, 95%CI 
1.55 to 4.86), tumor ulceration (HR 3.19, 95%CI 1.50 to 6.81), and lymphatic or vascular invasion 
(HR 1.72, 95%CI 1.05 to 2.83).  
Median OS was 496 days for all cats and was not significantly longer (p=0.191) for cats treated with 
BRM (623 days) compared with URM (455 days). (Fig 2)  
 
Figure 2: Kaplan Meier survival distribution for overall survival time in 111 cats with mammary 
carcinoma, according to type of mastectomy. Vertical ticks indicate censored observations.   
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On univariable Cox regression, tumor location, lymph node metastasis, treatment with 
chemotherapy and development of distant metastasis were associated (p>0.25) with OS.   
In the final multivariable model, risk factors for death included development of regional or distant 
metastasis (HR 2.34, 95%CI 1.36 to 4.00) and lymphatic or vascular invasion (HR 1.86, 95%CI 1.11 
to 3.10). Treatment with chemotherapy was associated with reduced hazard of death (HR 0.49, 
95%CI 0.29 to 0.81).  
Discussion  
It is generally agreed that surgery plays a pivotal role in the management of FMA as it does in human 
breast cancer. In cats many previous studies have attempted to elucidate the effects of different 
surgical approaches to the disease and some helpful data exists that has demonstrated that a local 
approach by simple or regional mastectomy is associated with a significantly shorter PFI compared 
to those treated by URM.(1)  
Despite radical mastectomy having become the standard of care, data on whether a unilateral or a 
bilateral approach should be performed, even in the event of unilateral disease, has been more 
controversial. Several studies have attempted to answer this question although none has concluded 
that unilateral mastectomy is an independent risk factor for diminished progression free interval or 
overall survival when considered in a multivariate statistical model. (4,6,7)  
In the current study progression-free interval for unilateral and bilateral radical mastectomy was 861 
and 298 days respectively and the unilateral approach was found to be an independent risk factor 
for local recurrence or metastatic spread of FMA.    
The analysis of outcomes in this study found a significantly higher complication rate for single 
session BRM (43.4%) compared to URM or staged BRM (24.1%). While the factors involved in 
wound healing of a staged bilateral radical mastectomy cannot be completely equated to those of 
having two separate unilateral procedures, they are probably more similar to each other compared 
to when a single -session bilateral procedure is performed. Single session bilateral radical 
mastectomy involves greater tissue removal and therefore greater wound tension at the margin. 
Greater tension leads to lower oxygen tension at the skin margins and predisposes to infection and 
dehiscence which was seen in a higher proportion of BRM cases in this study.    
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There are several limitations to this study. All tissue samples were reviewed by different pathologists 
at their home institutions. The histopathologic evaluation was not uniform and precluded further 
classification in terms of grading and analysis on the basis of histopathologic type. Cats were treated 
at multiple referral hospitals with different monitoring and follow-up. This could have caused the 
loss of some data. Due to the heterogeneity of adjuvant chemotherapy administered, we avoided 
investigating variable effects of single agents and rather grouped chemotherapy agents. This 
approach provides limited information on the efficacy of chemotherapy for treatment of FMC but 
this was not a primary aim of the study.  
Conclusion  
These findings support the use of BRM for treatment of FMA to improve the PFI although no 
significant effect of surgical approach on OS was found. To reduce complications associated with 
BRM, performing the procedure in a staged fashion is recommended. 
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Abstract 
Objective – To evaluate for associations between surgical approach and on complication rate, 
progression-free survival, and disease-specific survival in cats with mammary adenocarcinoma. 
Design – Multi-institutional retrospective study 
Animals – 107 client-owned cats 
Methods – Cats that underwent surgical excision of mammary adenocarcinoma by unilateral or 
bilateral (staged or single-session) mastectomy were included. Medical records were reviewed and 
relevant clinical data and details of surgical and adjuvant therapies were recorded. Outcome data 
obtained included post-operative complications, progression-free survival, and disease-specific 
survival.   
Result – Complications occurred in 12/61 (19.7%) cats treated with unilateral mastectomy, 5/14 
(35.7%) cats treated with staged bilateral mastectomy, and 13/32 (40.6%) cats treated with single-
session bilateral mastectomy and were significantly more likely to occur in cats undergoing bilateral 
versus unilateral mastectomy (p=0.027). Median progression-free interval was longer (p=0.004) for 
cats treated with bilateral mastectomy (542 days) compared with unilateral mastectomy (289 days). 
In the multivariable model, risk factors for disease progression included unilateral mastectomy, 
tumor ulceration, lymph node metastasis, and tumors arising in the fourth mammary gland. Risk 
factors for disease-specific death included lymph node metastasis and development of regional or 
distant metastasis. Among cats that did not develop metastasis, unilateral mastectomy was a risk 
factor for disease-specific death. Treatment with chemotherapy was associated with reduced hazard 
of disease-specific death. 
Conclusion – These findings support the use of bilateral mastectomy for treatment of feline 
mammary adenocarcinoma to improve the progression-free survival and disease-specific survival. 
Performing bilateral mastectomy in a staged fashion may help to reduce complication rate. 
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Introduction 
More than 80% of all mammary gland masses in cats are malignant and the behavior of these tumors 
is characterized by local invasion into the vasculature and surrounding tissues and by metastasis to 
draining lymph nodes and distant locations, such as lungs, pleura and liver.1-10 The aggressive 
biological behavior of FMA requires aggressive treatment. Treatment options that have been 
reported include surgical excision, chemotherapy, immunotherapy, radiation therapy, or 
combinations of these treatments.1-10 Numerous studies have evaluated prognostic factors for FMA 
and factors found to be significant in individual studies include tumor size,11,12 TNM stage,8 
histologic subtype,10,13 histologic grading,8,14 lymphatic invasion,3,8 as well as a variety of 
proliferative markers including mitotic index,8,15 Ki67 positivity,8 and mean AgNOR count per 
neoplastic cell.16 The administration of adjuvant chemotherapy has been suggested to have a 
beneficial prognostic effect in some studies,4 but in one study that included a control population that 
did not receive adjuvant chemotherapy, chemotherapy was not beneficial.6  
Surgical approach has been shown to positively affect disease-free-interval when full chain 
(sometimes referred to as radical) mastectomy is compared to regional mastectomy1, and based on 
this, a recommendation to perform full chain mastectomy of the affected mammary chain is well 
established regardless of tumor size. A more challenging question is whether to perform URM or 
BRM because of possible contact between individual glands, connections between the left and right 
mammary chains, or the de novo development of mammary adenocarcinoma in the contralateral 
chain that remains present.  
The lymphatic anatomy has been well studied in healthy cats. The drainage patterns of the different 
glands to their respective ipsilateral nodes has been established and studies broadly agree on these 
pathways.17-19 However, evidence for lymphatic cross-connections from ipsilateral to contralateral 
glands appears to be absent in all the studies currently published irrespective of which assessment 
techniques is used.17-19    
Bilateral mastectomy can be performed as a single-session procedure or in a staged fashion usually 
with the two procedures being performed several weeks apart. In one study, 37 cats undergoing 
staged BRM had longer disease-free interval than those undergoing UM (917 days versus 348 days), 
however, this result was only statistically different in the univariate model.4 Limited information 
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exists in the literature on cats treated with BRM for management of FMA and the complication rate 
associated with this procedure is largely unknown.     
The objectives of this multi-institutional retrospective study were to compare outcome among cats 
with mammary adenocarcinoma following excision with or without various systemic adjuvant 
therapies, and to evaluate the effect of surgical approach on progression-free survival (PFSI) and 
disease-specific survival (DSS). Our primary null hypothesis was that no difference would exist in 
PFSI and DSS between cats with mammary adenocarcinoma treated by BRM or URM. Secondary 
hypotheses were that no differences would exist in the surgical complication rate of URM versus 
BRM whether performed in a single-session or staged approach and that adjuvant chemotherapy 
would prolong the DSS in cats, compared with those receiving no systemic adjuvant therapy.  
Methods 
Animals - Cats diagnosed with mammary adenocarcinoma at nine veterinary institutions in North 
America and Europe between September 16th 1991 and September 1st 2014 were included in this 
study. Medical records were reviewed from the participating centers and telephone interviews were 
conducted with owners or referring veterinarians to assess long-term outcome. 
Criteria for selection of cases - Cats that had a complete medical record and underwent surgical 
excision of histopathologically confirmed mammary adenocarcinoma with URM or BRM (single 
session or staged) were included. Cats were excluded if they underwent local or regional 
mastectomy, if they underwent URM but had bilateral disease, or if they had distant metastasis at 
the time of surgery. However, cats with locoregional disease alone and no distant metastases were 
included. 
 
Case data - Information collected from the medical record included age at time of surgery, weight, 
sex, breed, use of progestins, previous pregnancy, whether an ovariectomy or ovariohysterectomy 
had been performed, and time from onset of clinical signs to presentation to a veterinarian. 
Information recorded from diagnostic imaging studies included abnormalities present on thoracic 
radiography and abdominal ultrasound prior to the first surgery. The number of mammary masses, 
location of mammary masses (right, left, or bilateral), and which specific gland(s) was affected (1-
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4) were recorded, along with the diameter of the largest mammary mass (measured in cm) and 
presence or absence of ulceration. From these results a TNM stage was designated for each cat based 
on the clinical and diagnostic imaging findings using the modified World Health Organization 
(WHO) staging system.1 
Surgical variables included the surgical procedure performed: URM, single session BRM, or staged 
BRM. Surgery time was recorded and, in the case of staged BRM, the surgery time for each of the 
two procedures was recorded as a separate event. If a lymphadenectomy was performed, the lymph 
nodes removed were noted. Intra- and post-operative complications were recorded and compared 
between procedures. 
The results of histological evaluation of all resected mammary gland tissue, as well as lymph nodes, 
was recorded. Margin evaluation, histologic grade based on the degree of differentiation, and 
evidence of lymphatic and vascular invasion was also recorded when available.   
The number of doses, dose range and type of chemotherapy drugs administered were recorded for 
each case. Whether or not the cat completed the prescribed course of chemotherapy was also 
recorded. 
Outcomes - Progression-free survival (PFSI) was defined as the time from mastectomy until 
documentation of local tumor progression, or regional, or distant metastasis, or tumor related death. 
When it occurred local progression was categorized as recurrence at or close to the previous surgical 
scar or at a location distant to the previous resection site. However, due to the challenges inherent 
in separating location of recurrence retrospectively these were grouped for statistical purposes as 
local progression. Progression-free survival time, as well as the nature of the progression (local 
versus distant), was also recorded. Disease-specific survival time (DSS) was defined as the time 
from original mastectomy to tumor-related death. Tumor-related death was defined as death or 
euthanasia due to local tumor recurrence, de novo tumor development, regional metastasis, or 
distant metastasis. For both PFSI and DSS, deaths associated with treatment or due to unknown 
causes were considered tumor-related. 
Statistical analysis - Baseline characteristics were examined and summary statistics described for 
all measured variables. Categorical variables were reported as numbers and percentages. Normal 
distribution of continuous variables was evaluated using histograms and the Shapiro-Wilk test, and 
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results were reported as mean (standard deviation) or median (range). Comparisons of baseline 
characteristics were made between mastectomy groups using 2 or Fisher exact tests for categorical 
variables, and independent t-tests or Mann-Whitney U-tests for continuous variables. For cats 
undergoing staged BRM, the surgery times for the first and second procedures were compared using 
the signed rank test for pairwise comparisons. All tests were two-sided and results were considered 
statistically significant if p  _< .05. 
Cats lost to follow-up or alive at the time of data collection were censored at their last recorded alive 
dates. Cats that died from documented causes unrelated to their mammary carcinoma were censored 
to minimize the influence of competing risks. Kaplan-Meier product limit method was used to 
describe unadjusted PFSI and DSS for all cats. Log rank tests were used to compare progression and 
survival distributions according to mastectomy type. Cox proportional hazard regression was used 
to model variables associated with PFSI and DSS. Univariate analyses were performed and 
covariates were retained if their likelihood ratio test or Wald test p values were _<.05, or if covariates 
were confounding the association of interest (defined as >15% change in hazard ratio); no covariates 
forced into the model on a priori basis. Two-way interactions between the main effects were 
investigated. In instances where the likelihood ratio test could not be used due to missing covariate 
data, Akaike information criterion (AIC) was used for model comparison. Proportional hazards 
assumptions were evaluated with Shoenfeld residuals using the score test, with p > .05 considered 
acceptable. Overall model fit was assessed using deviance and Cox-Snell residuals.  
Results 
General characteristics - Records of 116 cats treated with mastectomy were reviewed. Three cats 
were excluded due to the presence of distant metastasis prior to surgery, and 5 cats were excluded 
because a URM was performed without subsequent staged BRM despite the presence of bilateral 
FMA. One cat was excluded because it developed respiratory distress and died following single-
stage bilateral mastectomy and histopathology was not suBRMitted. Thus,107 cats from nine 
different veterinary hospitals were eligible for inclusion (Table 1). Sixty-one cats were treated with 
URM (57%), 32 cats with single-session BRM (30%), and 14 cats with staged BRM (13%). 
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Table 1 
Characteristics of 108 cats undergoing radical mastectomy for treatment of FMA, according to 
mastectomy type (URM vs BRM). Data are presented as number (%) except where indicted. 
 
 URM 
(n=61) 
BRM 
(n=46) 
P value 
Institution 
          University of Pennsylvania 
          University of California Davis 
          Colorado State University 
          Ontario Veterinary College 
          Alta Vista Animal Hospital 
          Clinica Veterinaria Nerviano 
          University of Turin 
          University of Florida 
          University of Tennessee 
Year Treated 
          1991-2006 
          2007-2014 
 
17 (27.9) 
16 (26.2) 
11 (18.0) 
3 (4.9) 
0 (0.0) 
7 (11.5) 
3 (4.9) 
3 (4.9) 
1 (1.6) 
 
24 (42.6) 
35 (57.4) 
 
11 (23.9) 
4 (8.7) 
7 (15.2) 
5 (10.9) 
9 (19.6) 
1 (2.2) 
3 (6.5) 
3 (6.5) 
3 (6.5) 
 
7 (15.2) 
39 (84.8) 
0.001 
 
 
 
 
 
 
 
 
 
0.003 
Age, y, mean (SD) 10.7 (2.8) 10.3 (3.5) 0.543 
Weight, kg, median (range) 4.3 (2.3-7.0) 4.0 (2.7-7.8) 0.15 
Sex    0.851 
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          Male castrated 
          Female intact 
          Female spayed 
1 (1.6) 
4 (6.6) 
56 (91.8) 
1 (2.2) 
2 (4.3) 
43 (93.5) 
Breed  
          Domestic short hair 
          Domestic long hair 
          Siamese 
          Other pure breed 
 
33 (54.1) 
17 (27.9) 
5 (8.2) 
6 (9.8) 
 
25 (54.3) 
8 (17.4) 
2 (6.4) 
11 (23.9) 
0.176 
Duration of clinical signs, d, median (range)1 30 (0-700) 21 (0-730) 0.750 
Number of tumors 
          1 
          2-5 
          >5         
 
40 (65.6) 
18 (38.3) 
3 (4.9) 
 
19 (41.3) 
18 (39.1) 
9 (19.6) 
0.016 
Location of tumors2 
          Right chain 
          Left chain 
 
34 (55.7) 
27 (44.3) 
 
17 (54.8) 
14 (45.2) 
1.000 
Largest tumor diameter, cm, median (range)3 2 (0.2-10.0) 2 (0.3-10.0) 0.365 
Ulcerated tumor 6 (9.8) 6 (13) 0.759 
TMN Stage4 
          Stage 1 (T1 N0, M0) 
          Stage 2 (T2, N0, M0) 
 
19 (31.7) 
16 (26.7) 
 
14 (31.8) 
7 (15.9) 
0.384 
   
 
32 
 
          Stage 3 (T1-2, N1, M0); (T3, any N, M0) 25 (41.7) 23 (52.3) 
Lymph node metastasis7 20 (33.3) 21 (44.7) 0.401 
Histopathologic lymphatic or vascular invasion5 26 (42.6) 20 (42.6) 1.000 
Histopathologic surgical margins6 
          R0 (clean) 
          R1 (narrow, <2mm) 
          R2 (dirty) 
 
41 (75.9) 
8 (14.8) 
5 (9.3) 
 
37 (90.2) 
3 (7.3) 
1 (2.4) 
0.226 
 
1: data missing for 19 cats; 2: 15 cats treated with BRM had masses located in both right and left 
chains; 3: data missing for 8 cats; 4: data missing for 2 cats; 5: data missing for 15 cats; 6: data 
missing for 12 cats 
 
Ninety-nine of 107 cats were neutered females, 6/107 were intact females and 2/107 were castrated 
males. The type of sterilization procedure was known for 44 neutered female cats: 28 cats (63.6%) 
had an ovariectomy and 16 cats (36.4%) had an ovariohysterctomy. Parturition status was known 
for 44 cats: 11 (25%) cats had at least one prior pregnancy and 33 (75%) cats were nulliparous. No 
cats had previously been treated with oral progestins. Tumor location was reported for 103 cats: the 
first (axillary) glands were involved in 33 (32%) cats, second (thoracic) glands were involved in 29 
(28.1%), third (abdominal) glands were involved in 40 (38.9%) cats, and 4th (inguinal) glands were 
involved in 58 (56.3%) cats. Tumors were located in more than one mammary gland in 34 (33%) 
cats.  
Three-view thoracic radiographs were performed in 93 (86.9 %) cats, and abdominal ultrasound in 
45 (42.1%) cats. No cases had evidence of distant metastasis on radiographs or ultrasound, although 
enlarged inguinal or iliac lymph nodes were noted in 9/45 cats. Regional lymph nodes were 
reportedly aspirated in 18 (16.8%) cats, but results were available for only 15 cats: cytology was 
positive for metastasis in 1/6 axillary nodes aspirated, 7/7 inguinal nodes aspirated, and 1/2 iliac 
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lymph nodes aspirated. Information about why certain staging tests were or were not performed in 
individual cats was not available.  
 
Surgery and histopathology - Surgical procedure time was reported in 88 cats. Median procedure 
time was 70 minutes (range, 40-160 minutes) for 58 URMs (including first stage of cats treated with 
staged BRMs), and 72.5 minutes (range, 35-165 minutes) for 31 single-session BRMs (p=0.798). 
Among cats treated with staged BRM, the median time between surgeries was 4 weeks (range 2.5-
7.0 weeks). Median second surgery time was 70 minutes (range 41 -115) in 9 cats for which surgery 
time was recorded and was not significantly different to the first surgical time (p=0.671). Regional 
lymph nodes were not removed in 14 cats. Superficial inguinal lymph nodes were removed in 64 
cats, and both inguinal and axillary lymph nodes were removed in 29 cats. Patterns of lymph node 
removal were not statistically different based on mastectomy technique (p=0.946).  
 
Post-operative complications occurred in 30 (28%) cats. (Table 2) One cat treated with URM 
experienced multiple complications (incisional infection and pleural effusion). Complications 
occurred in 12/61 (19.7%) cats treated with URM, 5/14 (35.7%) cats treated with staged BRM, and 
13/32 (40.6%) cats treated with single-session BRM; complications were significantly more likely 
to occur in cats undergoing BRM compared with R(p=0.027). Among staged bilateral cases, 
complications were associated with first surgery in 2 cats, second surgery in 2 cats, and both 
surgeries in 1 cat. More complications occurred in cats undergoing single-session BRM (13/32, 
40.6%) compared to URM or staged BRM (17/75, 22.7%), although the difference was not 
statistically significant (p=0.058). Two cats died in the immediate post-operative period: one cat due 
to cardiac arrest after unilateral mastectomy, and one cat due to respiratory failure attributed to 
excessive wound closure tension after single-session bilateral mastectomy.   
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Table 2: Post-operative complications in 107 cats undergoing URM or BRM for FMA. One cat 
experienced multiple complications, and 3 cats died related to complications. All values are reported 
as No. (%).  
 
 URM 
N=61 
BRM Staged  
N=14 
BRM Single-
stage  
N= 32 
Total 
N= 108 
Infection/dehiscence 9(14.8) 2 (14.3) 8 (25) 19(17.6) 
Seroma 1 (1.6) 1 (7.1) 3 (9.4) 5 (4.6) 
Abdominal hernia 1 (1.6) 0 (0.0) 1 (3.1) 2 (1.9) 
Respiratory distress 1 (1.6) 0 (0.0) 1 (3.1) 2 (1.9) 
Other 1 (1.6)1 2 (14.3)2 0 (0.0) 3 (2.8) 
1: cardiac arrest (1); 2: seizures (1), esophageal stricture (1) 
 
Tumor histopathology was available for all cats. Histopathologic evaluation and terminology used 
to describe tumors was not uniform across all surgical samples. The majority of tumors were 
described simply as adenocarcinoma, but other mammary carcinoma diagnoses were also reported 
including simple, cystic, tubular, tubulopapillary, tubuloacinar, papillary, ductal, intraductal, 
infiltrative, secretory, complex, lobular, basaloid, scirrous, and comedo carcinomas. Heterogeneity 
of descriptions precluded further classification and analysis on the basis of histopathologic subtype. 
Degree of differentiation was reported in 57 cats: 12 (21.1%) tumors were well differentiated, 21 
(36.8%) were moderately differentiated, and 24 (42.1%) were poorly differentiated.  Lymphatic 
invasion was reported in 43/107 (40.2%) cats and vascular invasion was reported in 16/107 (14.9%) 
cats. Tissue margins were evaluated in 95 cats and were clean (>2mm) in 78/95(82.1%) cats, narrow 
(0-2mm) in 11/95 (11.6%) cats, and incomplete in 6/95 (6.3%) cats. Among 93 cats for which 
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regional lymph nodes were evaluated histologically, 41 (44.1%) had evidence of lymph node 
metastasis.  
 
Adjuvant therapy - Follow-up information was analyzed for 105 cats that survived the post-operative 
period, including 60 cats treated with URM and 45 cats treated with BRM. Adjuvant chemotherapy 
was administered to 53 (50.5%) cats, including 28 (46.7%) cats treated with URMs and 25 (55.6%) 
cats treated with BRMs. There was no significant difference (p=0.432) in the proportion of cats 
receiving chemotherapy between the mastectomy groups. Doxorubicin was administered to 44 cats 
at recommended dosages for a median of 4 doses (range, 1-6 doses); eight of these cats were also 
treated concurrently with recommended doses of cyclophosphamide for a median of 4 doses (range, 
1-4 doses). Carboplatin was administered to 15 cats, including 12 that also received doxorubicin. 
The remaining six cats received other chemotherapy drugs, including experimental liposomes (2), 
epirubicin (2), mitoxantrone (1), and Palladia and chloarmbucil (1). Following doxorubicin and/or 
carboplatin chemotherapy, six cats were treated with additional chemotherapy: toceranib (2), 
vincristine (1), vinorelbine (1), dacarbazine (1), vincristine, toceranib, and chlorambucil (1). Among 
chemotherapy-treated cats, 40 (75.5%) completed their planned treatment protocol; treatment was 
stopped early in 13 cats due to progressive disease (6), non-tumor-related death (3), delayed post-
operative complications (1), kidney disease (1), persistent neutropenia (1), and owner relocation (1). 
NSAIDs (meloxicam or ketoprofen) were administered to 17 (15.7%) cats, including nine that were 
also treated with chemotherapy. 
 
Progression-free survival - Progressive disease was reported for 64 (61.0%) cats. Local recurrence 
and regional or distant metastasis was seen in 28/60 (46.7%) and 33/60 (55%) of cats respectively 
that underwent URM and 9/45 (20%) and 16/45 (35,6%) of cats respectively that underwent BRM. 
Local progression and regional or distant metastasis were more frequently reported following URM 
than BRM. (Table 3) Both local progression and metastasis was diagnosed in 17 cats treated with 
URM and 5 cats treated with BRM. Among these 22 cats, the first reported event was local 
progression in 12 cats and metastasis in 6 cats; in the remaining 4 cats both local progression and 
metastasis were identified concurrently. Location of local progression was not reported in 5 cats. 
Among the other 32 cats, recurrence developed close to the surgical site in 10 (40.0%) cats treated 
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with URM and 5 (71.4%) cats treated with BRM, and was at a different site within the mammary 
tissue in the remaining 17 cats (p=0.209). Among 95 cats for which surgical margins were reported, 
local progression was observed with 22/77 (28.6%) cats with clean margins, 5/11 (45.5%) of cats 
with narrow margins, and 4/6 (66.7%) cats with incomplete margins (p=0.035).  Site of metastasis 
was not reported in 2 cats. Metastatic disease was identified in the lungs (33/47, 70.2%), regional 
lymph nodes (15/47, 31.9%), and other distant sites (5/47, 10.6%) including the spleen, brain, 
peritoneal space, muscle, and sciatic nerve. 
 
Table 3: Reported disease progression in 107 cats undergoing URM or BRM for FMA. 22 cats 
developed both local recurrence and metastatic disease. All values are reported as No. (%) 
 
 URM 
N=61 
BRM 
N=46 
P value 
No progression 17 (27.9) 26 (56.5) 0.003 
Local recurrence1 
   Near surgical site 
   Distant to surgical site 
28 (46.7) 
10 (16.7) 
15 (25.0) 
9 (20.0) 
5 (11.1) 
2 (4.4) 
0.005 
Regional or distant metastasis2, 3 
    Lymph node 
    Lungs 
    Other distant site 
33 (55.0) 
15 (25.0) 
20 (33.3) 
3 (5.0) 
16 (35.6) 
2 (4.4) 
13 (28.9) 
2 (4.4) 
0.048 
1: Site of recurrence not reported in 3 URM and 2 BRM; 2: Site of metastasis not reported in 1 URM 
and 1 BRM; 3: Multiple sites of metastasis were reported in 4 URM and 2 BRM. 
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The overall median PFSI was 375 days, and was significantly longer (p=0.003) for cats treated with 
BRM (542 days) compared to URM (289 days). (Figure 1) On univariate Cox regression, institution, 
year, age, body weight, duration of clinical signs prior to radical mastectomy, post-operative incision 
infection, and treatment with chemotherapy were not associated with PFSI; tumor location, tumor 
ulceration, number of tumors, type of mastectomy, incomplete surgical margins, TMN stage, lymph 
node metastasis at the time of surgery, and lymphatic or vascular invasion were associated (p<0.25) 
with PFSI and were tested in the multivariate model. The final multivariable model included type 
of mastectomy, tumor ulceration, lymph node metastasis at the time of surgery, and tumor location, 
all of which had significant associations with PSI; no additional variables were retained as 
confounders. Interactions between the four retained variables were tested and there were no 
significant interactions. Risk factors for disease progression included URM (HR 3.09, 95% CI 1.67 
to 5.77), tumor ulceration (HR 4.35, 95% CI 1.81 to 10.42), lymph node metastasis at the time of 
surgery (HR 2.49, 95% CI 1.35 to 4.60), and tumor arising in a fourth (inguinal) gland (HR 2.25, 
95% CI 1.23 to 4.12). Although lymph node status was associated with progressive disease, 13/41 
(31.7%) with a positive lymph node at the time of surgery did not progress to further metastasis; the 
model indicated that BRM was protective against disease progression even when a positive lymph 
node was identified.  
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 Figure 1 
Kaplan Meier PFS estimates in 107 cats undergoing URM or BRM for treatment of FMA. 
Calculated functions are based on data for all cats, but the portion displayed ends at 1200 days given 
estimates beyond this point reflect data for only 4 cats and are not stable. Hashmarks indicate 
censored observations. 
 
Disease-specific survival - At the time of analysis, 54 cats had died from FMA(includes 2 deaths in 
the perioperative period and 2 deaths due to unknown causes), 25 were lost to follow-up (median 
298 days, range 17-3278 days), 16 were alive, and 12 had died from causes unrelated to FMA, 
including other neoplasia (4), cardiac disease (2), kidney disease (1), esophageal stricture (1), 
bacterial cholangitis (1), endocrine disease (1), iatrogenic injury (1), old age (1), and unknown 
causes (2). The overall median DSS was 596 days, and was significantly longer (p=0.027) for cats 
treated with BRM (1140 days) compared with URM (473 days) on unadjusted analysis. (Figure 2) 
On univariate Cox regression, institution, year, body weight, duration of clinical signs, number of 
tumors, tumor location, surgical margins, and development of local recurrence were not associated 
with survival time; age, type of mastectomy, tumor ulceration, TNM stage, lymphatic or vascular 
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invasion, lymph node metastasis at the time of surgery, treatment with chemotherapy, and 
development of regional or distant metastasis were associated (p<0.25) with DSS and were tested 
in the multivariate model. Age, tumor ulceration, lymphatic or vascular invasion, and TNM stage 
were excluded from the model, and interactions between the remaining 4 variables (type of 
mastectomy, lymph node metastasis at time of surgery, treatment with chemotherapy, and 
development of regional or distant metastasis) were tested. A significant interaction between type 
of mastectomy and development of metastasis was identified. Development of regional or distant 
metastasis after surgery was strongly associated with death (HR 10.52, 95% CI 2.79 to 39.68) in all 
cats. Among cats that did not develop metastasis, treatment with URM rather than BRM increased 
the hazard of death 4.57 times (HR 4.56, 95% CI 1.27 to 16.43). For cats developing post-operative 
metastasis, the type of mastectomy was not significantly associated with DSS (HR 0.73, 95% CI 
0.33 to 1.60). Lymph node metastasis at the time of surgery was also associated with increased 
hazard of death (HR 2.14, 95% CI 1.11 to 4.14), whereas treatment with chemotherapy was 
protective (HR 0.36, 95% CI 0.19 to 0.70).  
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Figure 2 
Kaplan Meier DSS estimates in 1075 cats undergoing URM or BRM for treatment of FMA. 
Calculated functions are based on data for all cats, but the portion displayed ends at 2000 days given 
estimates beyond this point reflect data for only 4 cats and are not stable. Hashmarks indicate 
censored observations. 
Discussion 
The current study documents clinicopathologic and therapeutic outcome data for the largest cohort 
of cats treated surgically for FMA reported in the veterinary literature. It is generally agreed that 
surgery plays a pivotal role in the management of FMA as it does in human breast cancer. Many 
previous studies have attempted to elucidate the effects of different surgical approaches to the 
disease and some helpful data exists that has demonstrated that local or regional mastectomy is 
associated with a significantly shorter disease-free interval compared to those treated by URM.1 
Despite full chain mastectomy having become the standard of care, data on whether a unilateral or 
a bilateral approach should be performed even in the event of unilateral disease has been more 
controversial. Several studies have attempted to answer this question although none has concluded 
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that URM is a risk factor for diminished PFSI or DSS or overall survival when considered in a 
multivariate statistical model that considers other known risk factors. One study documented a PFSI 
of 793 days versus 115 days for BRM versus URM, however, only 3 cats underwent BRM and so 
no significant differences were found.6 A second study compared BRM, URM and regional 
mastectomy and reported disease-free interval of 917 days, 348 days, and 428 days, respectively.4 
Despite there being a significant difference on univariate analysis between BRM and URM, this 
difference was insignificant on multivariate analysis. In the current study, PFSI for BRM and URM 
was 542 and 289 days, respectively, and URM was found to be an independent risk factor for local 
recurrence or metastasis.   
The relatively higher incidence of local recurrence seen in this cohort of cats with mammary 
adenocarcinoma undergoing URM versus BRM could have a number of explanations. In human 
breast cancer, for which FMA has previously been considered a good animal model,20,21 much 
debate has surrounded the indications for contralateral prophylactic mastectomy (CPM) the human 
corollary to BRM in cats. The use of CPM has been increasing in large part due to fear of recurrence 
in the contralateral breast in women with invasive ductal carcinoma and the increasing use of 
magnetic resonance imaging of the contralateral breast that can detect occult lesions that may not 
be clinically significant causes of longer term morbidity.22,23 The therapeutic benefit of CPM in the 
majority of women with early stage breast cancer is likely to be small as the incidence of 
contralateral breast cancer has been reported to be around 3-10% and has been declining in recent 
years.24,25 There are, however, certain subgroups of women who have a much higher risk of 
contralateral breast cancer who benefit from CPM, such as those with BRCA1 or BRCA2 genetic 
mutations and women who have a strong family history of at least two first-degree relatives with 
breast or ovarian cancer.23 In women with BRCA1 and BRCA2 mutations that undergo CPM, a 91% 
reduction for the development of contralateral breast cancer was documented in one study, although 
no improvement in overall survival was reported.26 The role of genetic mutations in FMA has not 
been as extensively studied as it has in women, and BRCA1 and BRCA2 mutations were not detected 
in a study evaluating five cats.21 Women with so-called triple-negative breast cancer (TNBC) are 
also at higher risk of recurrence and distant metastasis and have a poorer outcome than other forms 
of breast cancer.27 Tumor cells in TNBC lack estrogen and progesterone receptors as well as 
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overexpression of Her-2/neu, a transmembrane receptor that is encoded by the Her-2/neu 
protooncogene. In one study, 14 of 24 FMAs were classified as triple negative based in 
immunohistochemical staining suggesting that certain FMAs might behave biologically similar to 
TNBC.28 Expression of Her-2/neu has also been associated with breast cancers demonstrating more 
aggressive biologic behavior in women,29 but data on Her-2/neu overexpression in cats is limited 
and conflicting. However, at least one study has documented overexpression of Her-2/neu in FMA 
and correlated it with reduced overall survival compared to Her-2/neu negative FMA.28 The reasons 
why cats treated with BRM compared to those treated with URM develop fewer local recurrences, 
regional metastases, or distant metastasis is difficult to explain, but there may be a disease-
modifying effect of contralateral mastectomy. Similar findings have emerged from meta-analyses 
of women with the most aggressive forms of breast cancer.30 Prolongation of PFI has been 
demonstrated in women who undergo CPM, although no effect on overall survival was 
documented.30 Further work needs to be done on the molecular genetics of FMA but the high 
incidence of local recurrence reported here mirrors the outcomes seen for the most aggressive 
subsection of human breast cancers.  
The lymphatic drainage of the feline mammary glands forms one of the primary routes for 
locoregional metastasis in FMA. Lymphatic invasion and lymph node metastasis is one of the 
principal independent risk factors for overall survival in cats.10 Several studies have evaluated 
lymphatic anatomy and found fairly repeatable patterns of lymphatic drainage from the mammary 
glands of healthy cats using either in vivo computed tomography indirect lymphography using a 
contrast media or indirect injection of india ink.17-19 Generally the first two mammary glands drain 
to the accessory axillary lymph node, the third mammary gland can drain to either the axillary or 
superficial inguinal lymph node, and the fourth mammary gland drains to the superficial inguinal 
node. Less commonly the third and fourth glands can drain to the medial iliac nodes.18 A significant 
number of the first three mammary glands also drain to the cranial sternal nodes.17 Interestingly, 
none of these studies was able to demonstrate any connections between the left and right mammary 
chains making lymphatic metastasis to the contralateral mammary chain conceivably less likely. It 
should be remembered that all these studies were performed in healthy cats and it may be possible 
that lymphangiogenesis in cats with mammary carcinomas enhances the possibility of contralateral 
lymphatic metastasis. However, one study that evaluated VEGFR-3 levels on the intratumoral and 
   
 
43 
 
extratumoral stroma of benign and malignant FMA samples found no evidence for enhanced 
lymphangiogenesis and suggested that lymphatic metastasis occurs through the pre-existing 
lymphatic channels.31 
The oncological outcomes associated with the different surgical approaches for treatment of FMA 
may also be in part a function of the adequacy of local resection. In this study, incomplete or narrow 
(< 2mm) surgical margins were reported in 24.1% and 9.7% of URM and BRM procedures, 
respectively, although this difference was not statistically different. Whether or not part of the 
difference in PFI seen in this study was driven by the adequacy of local resection is difficult to say 
but improvement in the extent of local resection may be another reason to consider BRM for the 
management of FMA. 
Little attention has been paid to the complications associated with the different surgical approaches 
for resection of FMAs. Single-session BRM has rarely been reported in the literature with most 
studies involving BRM reporting the results of the staged procedure. In this study cats undergoing 
URM had fewer complications compared to those undergoing BRM overall (p=0.027). This analysis 
found more complications in the cohort of cats undergoing single-session BRM (40.6%) compared 
to URM or staged BRM (22.7%) although the difference did not reach significance (p=0.058). While 
the factors involved in wound healing of a staged BRM cannot be completely equated to those of 
having two separate unilateral mastectomies, they are probably more similar to each other compared 
to when a single-session bilateral procedure is performed. Single-session BRM is a much more 
aggressive surgical procedure and most surgeons would agree that there is subjectively greater 
wound tension following primary closure. Greater tension leads to lower oxygen tension at the skin 
margins, slows healing and predisposes to dehiscence, which was seen in a higher proportion of 
BRM cases compared to URM or staged BRM cases in this study. One cat died in the post-operative 
period due to respiratory failure in which excessive closure tension was thought to play a role. 
This study found a beneficial effect of adjuvant chemotherapy on DSS in FMA when all drugs were 
grouped together. The majority of cats (46 of 55, 84%) received doxorubicin-based protocols. 
Analysis of the data by type of chemotherapy drug administered was not performed due to the small 
numbers of cats that received drugs other than doxorubicin. The only other study comparing cats 
with FMA treated with surgery alone and surgery and chemotherapy did not find a significant effect 
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of the administration of adjuvant chemotherapy on overall survival times, however cats treated with 
URM and chemotherapy had significantly longer survival times than cats treated with URM alone.6 
In women it is generally accepted that chemotherapy has a beneficial effect in aggressive forms of 
breast cancer and, because there are similarities between aggressive breast cancer in women and 
FMA, in combination with the results of the present study, support the use of adjuvant chemotherapy 
in cats with FMA. Further prospective studies are needed to evaluate the effects of surgical 
approach, different chemotherapy protocols as well as other forms of adjuvant therapy in cats with 
FMA. It is plausible that certain subpopulations of cats with different types of FMA would benefit 
from individually tailored therapies. Larger studies as well as studies of molecular profiling and 
genomics will be necessary to identify these subpopulations and their potential therapeutic targets, 
a process which is already well under way in human breast cancer research. 
There are a number of limitations to this study. Tissue samples were reviewed by different 
pathologists most likely using different tissue processing techniques. The histopathologic evaluation 
was not uniform and precluded further classification in terms of grading and analysis on the basis 
of histopathologic subtype. Grouping local recurrence at the surgical scar and de novo tumor 
development in mammary tissue that remains after surgery as local progression is a significant 
weakness of the study. These two different forms of local progression are ideally important to 
differentiate and they may affect interpretation of some of the data such as the effect of surgical 
margin evaluation on outcomes. Unfortunately in a retrospective study it is very difficult to discern 
local recurrence from de novo tumor development from medical records alone. Cats were treated at 
multiple referral hospitals with different monitoring and follow-up, and allocation to treatment was 
not random. Necropsy data was generally not available, necessitating interpretation of medical 
records to determine cause of death or euthanasia; it is possible that some deaths were incorrectly 
categorized, although we were careful to consider all deaths FMA-related unless medical records 
strongly supported an alternative cause. We did not attempt to investigate effects of treatment in 
different FMA subgroups due to the small group sizes and the potential for systematic biases 
inherent in the retrospective study design; however, it is possible that the optimal treatment approach 
could differ among cats with different disease features. Due to the heterogeneity of adjuvant 
chemotherapy protocols administered, we avoided investigating variable effects of single agents 
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and grouped chemotherapy agents. This approach provides limited information on the efficacy of 
specific chemotherapy protocols for the adjunctive treatment of FMA. 
Conclusion 
In conclusion, the findings of this study support the use of the BRM for treatment of FMA in order 
to improve the PFSI and DSS. Performing BRM in a staged fashion may help to reduce 
complications. 
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